3 March 2023
Oncimmune Holdings plc
("Oncimmune" or the "Company")
Posting of Annual Report and Notice of General Meeting
Oncimmune Holdings plc (AIM: ONC.L), the leading global immunodiagnostics group, gives notice that its Annual Report and Accounts for the financial period ended 31 August 2022 (the "Annual Report") has today been sent to shareholders along with notice of a General Meeting ("GM"). The business of the GM will be, amongst other things, to receive the Annual Report and to approve the report on Directors' remuneration. The GM will be held at 10:00 am GMT on 27 March 2023 at the offices of Pinsent Masons LLP, 30 Crown Place, Earl Street, London, EC2A 4ES.
The Company's Annual Report and Accounts for the financial period ended 31 August 2022 and the Notice of GM can also be viewed on the "Investors" section of the Company's website at www.oncimmune.com.
For further information:
Oncimmune Holdings plc
Dr Adam M Hill, Chief Executive Officer
Matthew Hall, Chief Financial Officer
Singer Capital Markets (Nominated Adviser and Joint Broker)
Aubrey Powell, Harry Gooden, George Tzimas, James Fischer
+44 (0)20 7496 3000
Zeus (Joint Broker)
Dominic King, Victoria Ayton, Dan Bate
+44 (0)20 3829 5000
For more information, visit www.oncimmune.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
